Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRAT: +33 228073710
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
713
Stocks News & Analysis
stocks
Wildly overvalued ASX stock is skating on thin ice
stocks
Uber flexes its network effect and delivers strong result
stocks
Ask the analyst: Are Qantas shares a value trap?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,102.00 | 9.10 | -0.10% |
CAC 40 | 7,709.32 | 74.29 | 0.97% |
DAX 40 | 24,192.50 | 268.14 | 1.12% |
Dow JONES (US) | 43,968.64 | 224.48 | -0.51% |
FTSE 100 | 9,100.77 | 63.54 | -0.69% |
HKSE | 25,081.63 | 171.00 | 0.69% |
NASDAQ | 21,242.70 | 73.27 | 0.35% |
Nikkei 225 | 41,059.15 | 264.29 | 0.65% |
NZX 50 Index | 12,876.02 | 11.08 | -0.09% |
S&P 500 | 6,340.00 | 5.06 | -0.08% |
S&P/ASX 200 | 8,831.40 | 12.30 | -0.14% |
SSE Composite Index | 3,639.67 | 5.67 | 0.16% |